Interviewer: Professor Crowe, thank you for doing this interview with us
today to update us on the work being done by you and
your team, on SARS-CoV-2 human monoclonal antibodies for the COVID-19 pandemic.
Could you please give an overview on how the work in your lab has
developed since your last interview with us in May 2020?
Prof. Crowe: Yes, thanks for having me back, its been a year,
it's interesting to look back and see where we were then and where we are now.
In May 2020, we were just completing a massive series
of what we call 'sprint' antibody discoveries, where we worked as hard as possible,
our people were up here 20 hours a day,
some of them didn't take a day off for months until May.
We discovered thousands of antibodies, and down-selected to a panel of a dozen or so.
We partnered with various companies and groups to put those into clinical trials.
Now a year later, we're seeing the completion of much of that original work.
Right now, I think there are six phase III efficacy trials with our partner AstraZeneca.
There's prevention, post-exposure prophylaxis,
mild-to-moderate disease, and then hospitalized disease and so on.
Some of those trials are fully enrolled and we'll hear the answer.
We've been supporting those clinical trial programs
with AstraZeneca and also IDBiologics, and
then the United States government through JPO and their contractor
Ology is doing trials in the Department of Defense.
Lots of clinical trials going on and we
have high expectations that these will be beneficial,
but now we're turning to things like variants.